Quality Systems – Page 88

Supplier deviation not assessed during QA review – GDP documentation do’s and don’ts

Assessing Supplier Deviations During QA Reviews: An Investigation Guide In pharmaceutical manufacturing, the failure to adequately assess supplier deviations during Quality Assurance (QA) reviews can pose significant risks to product…

Training evidence weak during regulatory inspection readiness – GDP documentation do’s and don’ts

Addressing Weak Training Evidence During Regulatory Inspections in Pharma In the pharmaceutical industry, the robustness of training documentation is paramount for compliance during regulatory inspections. Weak training evidence can lead…

Quality event trending ignored during regulatory inspection readiness – FDA/MHRA inspector questions to prepare for

Addressing Ignored Quality Event Trends for Effective Regulatory Inspection Readiness The quality control landscape in pharmaceutical manufacturing is fraught with challenges, particularly when signals indicating quality events are overlooked or…

Quality event trending ignored during batch release decision – GDP documentation do’s and don’ts

Addressing Quality Event Trending Oversights in Batch Release Decisions In the pharmaceutical manufacturing sector, the oversight of quality event trending during batch release decisions can pose significant compliance risks. Quality…

Audit finding not escalated during management review – GDP documentation do’s and don’ts

“`html Failed to Escalate Audit Findings During Management Review: Investigating the Causes and Solutions Despite diligent efforts in quality assurance, audit findings can occasionally go unnoticed or lack appropriate escalation…

Inconsistent SOP interpretation during QA review – regulatory expectation gap and how to fix it

Addressing Gaps in SOP Interpretation During QA Review to Ensure Regulatory Compliance In the complex landscape of pharmaceutical manufacturing and quality assurance, inconsistent interpretation of Standard Operating Procedures (SOPs) during…

Inadequate risk assessment during batch release decision – regulatory expectation gap and how to fix it

Understanding and Addressing Inadequate Risk Assessments in Batch Release Decisions In the ever-evolving landscape of pharmaceutical manufacturing, the integrity of batch release decisions is paramount. A prevalent issue is inadequate…

Audit finding not escalated during management review – FDA/MHRA inspector questions to prepare for

Addressing Escalation Issues of Audit Findings During Management Review In pharmaceutical operations, the effective management of audits is crucial for ensuring compliance with regulatory expectations. An audit finding that is…

Batch disposition delayed during internal audit follow-up – FDA/MHRA inspector questions to prepare for

Managing Delays in Batch Disposition Following Internal Audits: A Comprehensive Investigation Approach Batch disposition delays during internal audits can trigger significant operational challenges in pharmaceutical manufacturing. When regulatory inspectors from…

Quality event trending ignored during internal audit follow-up – FDA/MHRA inspector questions to prepare for

How to Address Ignored Trending of Quality Events During Audit Follow-Up In the pharmaceutical industry, the oversight of quality events can have significant implications, especially when they are overlooked during…

Inconsistent SOP interpretation during internal audit follow-up – how to prevent repeat observations

Addressing Inconsistent SOP Interpretation Observations During Internal Audits Inconsistent interpretation of Standard Operating Procedures (SOPs) can lead to significant complexities during internal audits, resulting in repeated observations that may escalate…

Training evidence weak during management review – risk-based justification template for decisions

Weak Training Evidence: Strategies for Management Review Risk-Based Justification The issue of inadequate training evidence during management reviews frequently signals deeper systemic flaws in quality assurance (QA) systems. As companies…